Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Early mortality and prognostic factors in diffuse large B-cell lymphoma presenting with hemophagocytic lymphohistiocytosis

Jianai Sun, De Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 5456.

https://doi.org/10.1182/blood-2025-5456

Published: 2025

Journal Articles

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Peipei Ye, Renzhi Pei, Lihong Shou, Jie Jin, Hongyan Tong, Huifang Jiang, Linlong Xu, Jian Shen, Sai Chen, Gongqiang Wu, Dong Chen, Shuangyue Li, Jingcheng Zhang, Huang Li, Fujiang Song, Weiying Feng, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 5960.

https://doi.org/10.1182/blood-2025-5960

Published: 2025

Journal Articles

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia

Xueying Yang, Xin Huang, Jiejing Qian, Xingnong Ye, Gaixiang Xu, Wenjuan Yu, Mixue Xie, Hongyan Tong, De Zhou

Blood (2025) 146 (Supplement 1): 7149.

https://doi.org/10.1182/blood-2025-7149

Published: 2025

Journal Articles

Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes

Wei Wang, Yingwan Luo, Wei Lang, Wenbin Yang, Hongyan Tong

Blood (2025) 146 (Supplement 1): 5617.

https://doi.org/10.1182/blood-2025-5617

Published: 2025

Journal Articles

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Xuewu Zhang, Yunfei Lv, Xiang Zhang, Xingnong Ye, Chunmei Yang, Juying Wei, De Zhou, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 3596.

https://doi.org/10.1182/blood-2025-3596

Published: 2025

Journal Articles

Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations

Lingxu Jiang, Li Ye, Xin Huang, Xinping Zhou, Wei Wang, Lu Wang, Yudi Zhang, Jie Sun, Hongyan Tong

Blood (2025) 146 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2025-3833

Published: 2025

Journal Articles

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Jian Huang, Tian Zeng, Xiudi Yang, Xingli Zhao, Guangxun Gao, Hu Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2025-2034

Published: 2025

Journal Articles

Single-cell transcriptomics reveals monocytic glycolytic reprogramming in lymphoma-associated hemophagocytic lymphohistiocytosis

Xuelian Hu, Liangshun You, De Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 1208.

https://doi.org/10.1182/blood-2025-1208

Published: 2025

Journal Articles

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study

Chen Mei, Guifang Ouyang, Yanjuan Lin, Min Zhang, Minming Li, Hongyan Tong

Blood (2025) 146 (Supplement 1): 492.

https://doi.org/10.1182/blood-2025-492

Published: 2025

Journal Articles

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

Yile Zhou, Liu Ge, Liping Mao, Yinjun Lou, Hao Ai, Qian Wang, Hongyan Tong, Jie Jin, Qingsong Yin, Huafeng Wang

Blood (2025) 146 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2025-3336

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Linjie Li, Beili Hu, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2025-1911

Published: 2025

Journal Articles

Characteristics of diffuse large B-cell Lymphoma patients with rituximab induced acute thrombocytopenia

Jianai Sun, De Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 7217.

https://doi.org/10.1182/blood-2025-7217

Published: 2025

Journal Articles

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Xiaojing Bao, Tian Zeng, Zhikang Zheng, Bingbing Wen, Rumeng Li, Hongyan Tong, Jie Jin, Jian Huang

Blood (2025) 146 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2025-7352

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial

Liya Ma, Wenli Yang, Xinping Zhou, Li Ye, Gaixiang Xu, Chao Hu, Hongyan Tong

Blood (2025) 146 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2025-5637

Published: 2025

Journal Articles

Lipid metabolism disorders and immune metabolic programming in patients with idiopathic multicentric Castleman disease

Jiaying Ge, Xuejiao Yin, Yi Liu, Shengnan Ding, Qiumei Yao, Li Zhu, Min Yang, Zhenbo Wang, Xiaojun Peng, Tian Tong, Haitao Meng, Hongyan Tong, Liangshun You

Blood (2025) 146 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2025-3004

Published: 2025

Journal Articles

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Feng Zhu, Yile Zhou, Yi Zhang, Liping Mao, Yinjun Lou, Yu Zhu, Zheng Ge, Zhiyong Zeng, Fengbo Jin, Tingting Liu, Haitao Xu, Yue Yao, Quanyi Lu, Jianxin Guo, Hongyan Tong, Huafeng Wang, Jie Jin

Blood (2025) 146 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2025-1728

Published: 2025

Journal Articles

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Neng Nie, Chen Yang, Jun Shi, WANG Shunqing, Ruiqing Zhou, Hongyan Tong, Hong Chang, Dong You, Jin Chen, Jing Hao, Bing Han

Blood (2025) 146 (Supplement 1): 381.

https://doi.org/10.1182/blood-2025-381

Published: 2025

Journal Articles

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Xiangjie Lin, Di Xu, Nanfang Zhuo, Jingrui Jin, Yujia Wang, Liping Mao, Yinjun Lou, Min Yang, Haitao Meng, Wanzhuo Xie, Jian Huang, Hongyan Tong, Shengli Xue, Yu Zhu, Jie Jin, Jun Wang, Huafeng Wang

Blood (2025) 146 (Supplement 1): 7954.

https://doi.org/10.1182/blood-2025-7954

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early mortality and prognostic factors in diffuse large B-cell lymphoma presenting with hemophagocytic lymphohistiocytosis

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia

Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Single-cell transcriptomics reveals monocytic glycolytic reprogramming in lymphoma-associated hemophagocytic lymphohistiocytosis

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Characteristics of diffuse large B-cell Lymphoma patients with rituximab induced acute thrombocytopenia

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial

Lipid metabolism disorders and immune metabolic programming in patients with idiopathic multicentric Castleman disease

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only